Krystal Biotech Revenue and Competitors
Estimated Revenue & Valuation
- Krystal Biotech's estimated annual revenue is currently $21.5M per year.
- Krystal Biotech's estimated revenue per employee is $119,033
- Krystal Biotech's total funding is $386M.
- Krystal Biotech has 181 Employees.
- Krystal Biotech grew their employee count by 65% last year.
Krystal Biotech Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Krystal Biotech?
Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases. Our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. We work to accomplish that through scientific innovation, operational excellence and believe that ?nature operates in the shortest way possible?. (Aristotle)keywords:N/A
Number of Employees
Employee Growth %
Krystal Biotech News
Get Krystal Biotech alerts: This table compares Krystal Biotech and iTeos Therapeutics' net margins, return on equity and return on assets.
PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies,...
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine.
PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy can ...
PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|